Dosing & Uses
Dosage Forms & Strengths
- 25mg/mL (product discontinued)
Discontinued by manufacturer (4/4/2012)
Premedicate to prevent hypersensitivity reactions (e.g., dexamethasone, diphenhydramine, H2 blockers)
Moderate renal impairment: Dose adjustment not provided by manufacturer's labeling; monitor renal status
Severe renal impairment: Contraindicated
Frequency Not Defined
Lower extremity edema
Anorexia, nausea, vomiting, abdominal cramping
Hypocalcemia, hypophosphatemia, decreases bicarbonate
Black Box Warnings
Concurrent use of gallium nitrate with other potentially nephrotoxic drugs (eg, aminoglycosides, amphotericin B) may increase the risk for developing severe renal insufficiency in patients with cancer-related hypercalcemia. If use of a potentially nephrotoxic drug is indicated during gallium nitrate therapy, gallium nitrate administration should be stopped and hydration continued for several days after administration of the potentially nephrotoxic drug.
Serum creatinine and urine output should be closely monitored during and after therapy. Discontinue therapy if the serum creatinine level exceeds 2.5 mg/dL.
Severe renal impairment (serum creatinine >2.5 mg/dL)
Therapy may result in mild-to-moderate or asymptomatic hypocalcemia (discontinuation of therapy may be necessary)
Use caution in cardiovascular disease
Discontinue therapy during treatment with nephrotoxic drugs
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Excretion in milk unknown; not recommended
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Inhibits calcium resorption from bone by inhibiting osteoclast activity
Onset: 24-48 hr (initial); 5-9 (achieve normocalcemia)
Duration: 7-10 days
Steady-state: levels in 24-48 hr
Half-life: 105 hr (continuous infusion)
Vdss: 670 L/m²
Excretion: Urine (primary)
Mfr recommends that the calculated daily dose of gallium nitrate injection be diluted, preferably in 1 L NS or D5W
Administer by slow IV infusion
Infuse over a 24 hr period
Protect from light
Protect from freezing
Do not refrigerate